Senderowicz A - Search Results

1

Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

Pearson AD, Stegmaier K, Bourdeaut F, Reaman G, Heenen D, Meyers ML, Armstrong SA, Brown P, De Carvalho D, Jabado N, Marshall L, Rivera M, Smith M, Adamson PC, Barone A, Baumann C, Blackman S, Buenger V, Donoghue M, Duncan AD, Fox E, Gadbaw B, Hattersley M, Ho P, Jacobs I, Kelly MJ, Kieran M, Lesa G, Ligas F, Ludwinski D, McDonough J, Nikolova Z, Norga K, Senderowicz A, Taube T, Weiner S, Karres D, Vassal G. Pearson AD, et al. Among authors: senderowicz a. Eur J Cancer. 2020 Nov;139:135-148. doi: 10.1016/j.ejca.2020.08.014. Epub 2020 Sep 26. Eur J Cancer. 2020. PMID: 32992153 Review.

2

Societal challenges of precision medicine: Bringing order to chaos.

Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD-Faculty. Salgado R, et al. Eur J Cancer. 2017 Oct;84:325-334. doi: 10.1016/j.ejca.2017.07.028. Epub 2017 Sep 4. Eur J Cancer. 2017. PMID: 28865260 Free PMC article.

3

Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.

Kummar S, Doroshow JH, Tomaszewski JE, Calvert AH, Lobbezoo M, Giaccone G; Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Kummar S, et al. Eur J Cancer. 2009 Mar;45(5):741-6. doi: 10.1016/j.ejca.2008.10.024. Epub 2008 Dec 16. Eur J Cancer. 2009. PMID: 19091546 Free PMC article. Review.

4

Senderowicz AM, Pfaff O. Senderowicz AM, et al. Clin Cancer Res. 2014 Mar 15;20(6):1445-52. doi: 10.1158/1078-0432.CCR-13-1761. Clin Cancer Res. 2014. PMID: 24634467

5

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228.

Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, Bates SE. Sandor V, et al. Among authors: senderowicz a. Br J Cancer. 2000 Sep;83(6):817-25. doi: 10.1054/bjoc.2000.1327. Br J Cancer. 2000. PMID: 10952788 Free PMC article.

6

Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.

Robey RW, Medina-Pérez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE. Robey RW, et al. Among authors: senderowicz am. Clin Cancer Res. 2001 Jan;7(1):145-52. Clin Cancer Res. 2001. PMID: 11205902

7

Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.

Senderowicz AM. Senderowicz AM. Invest New Drugs. 1999;17(3):313-20. doi: 10.1023/a:1006353008903. Invest New Drugs. 1999. PMID: 10665481 Review.

8

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.

Zhai S, Senderowicz AM, Sausville EA, Figg WD. Zhai S, et al. Among authors: senderowicz am. Ann Pharmacother. 2002 May;36(5):905-11. doi: 10.1345/aph.1A162. Ann Pharmacother. 2002. PMID: 11978170 Review.

9

Preclinical and clinical development of cyclin-dependent kinase modulators.

Senderowicz AM, Sausville EA. Senderowicz AM, et al. J Natl Cancer Inst. 2000 Mar 1;92(5):376-87. doi: 10.1093/jnci/92.5.376. J Natl Cancer Inst. 2000. PMID: 10699068 Review.

10

Novel small molecule cyclin-dependent kinases modulators in human clinical trials.

Senderowicz AM. Senderowicz AM. Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S84-95. Cancer Biol Ther. 2003. PMID: 14508085 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters